

defensins and cancer

This manuscript ([permalink](#)) was automatically generated from [Jonzalez/rev@39bc33b](#) on May 13, 2020.

Authors

- **Jonathan Gonzalez**

 [XXXX-XXXX-XXXX-XXXX](#) ·  [jonzalez](#)

Department of Something, University of Whatever · Funded by Grant XXXXXXXX

- **None**

 [XXXX-XXXX-XXXX-XXXX](#)

Department of Something, University of Whatever; Department of Whatever, University of Something

Abstract

In humans, endogenous Antimicrobial peptides (AMP) are part of the immune system and act against pathogens. Defensins compose a class of AMPs that have activity against gram-positive and -negative bacteria and viruses. Their role in innate immunity as microbicidal and immunoregulatory agents that orchestrate cross-talk with the adaptive immune system, and, most recently, their association with cancer. Defensins produced by cells in the course of innate host defence serve as signals which initiate, mobilise, and amplify adaptive immune host defences. Linkage of defensins to weak tumour antigens potentiates their immunoadjuvant effects. Defensins use multiple cellular receptors, which endows them with the capacity to marshal adaptive host defences against microbial invaders. Recently, findings related to specific activation pathways of some of defensins have led investigators to associate them with pro-tumoral activity, contributing to a tumorigenic microenvironment. This review summarizes current knowledge of defensins to discuss their role in tumour growth, tumour monitoring and cancer treatment, is substantial interest in the identification of circulating human tumor-derived proteins in serum for the purposes of early cancer diagnosis.

Introduction

The AMP are polypeptides of fewer than 100 amino acids contain a positive net charge (from +2 to +9), high lysine and arginine content, and a significant number of hydrophobic residues ($\geq 30\%$) [1](#).

These properties permit the peptides to fold into amphipathic conformations upon contact with cell membranes, and the positively charged polar face help the molecules bind to the membrane through electrostatic interaction with the negatively charged head groups of phospholipids [2](#).

AMP have been isolated and characterized from a wide range of animal, plant and bacterial species and are known to play important roles in the host defence system and innate immunity [3](#)

The history of AMPs dates back to 1922 with the discovery of lysozyme by Alexander Flemming. The first reported animal originated AMP is defensin, which was isolated from rabbit leukocytes in 1956 [4](#). at the same time, it was also proven that human leukocytes contain AMPs in their lysosomes.

for mammals, there are two main genetic categories for AMP, have been implicated in antimicrobial activity of phagocytes, inflammatory and epithelial secretions. Defensins are widely distributed in epithelial cells and phagocytes, [5](#). Cathelicidins are structurally and evolutionarily distinct antimicrobial peptides that are similar to defensins in abundance and distribution [6](#)

The great diversity of AMP differs from one animal species to another. In this review I will focus on defensins because, defensins are particularly prominent in humans, as evidenced by the large number of expressed human genes [6](#), the various forms that are present in human tissues, and the ubiquitous occurrence of defensins in inflamed or infected human tissues [1](#).

Subclasses and antimicrobial activity defensins

Mammalian defensins are cationic AMP, with relatively arginine-rich nonglycosylated peptides with a molecular mass of 3.5–4.5 kDa. Their structure typically contains three intramolecular disulphide bridges between six cysteine residues [7](#). As mentioned for AMP in general, the classification of defensins is based on their structure, which divides them into three groups: α -defensins, β -defensins, and θ -defensins. In α -defensins, intramolecular bonding occurs between cysteines 1-6, 2-4, and [8](#), whereas in β -defensins it is between 1-5, 2-4, and 3-6 [9](#). Human defensins are produced in leukocytes and are also secreted by different epithelial cells and mucosal tissues. These human peptides have antimicrobial activity against a large number of gram-positive and -negative bacteria, fungi, and viruses [10](#). (table 1)

Although these disulfide bonds in cytheins appear to have a close relationship with microbial activity, it has been reported that the three disulfides or the order of connectivity is not an essential characteristic for activity in defensins, since even if cytokines defend them they still have antimicrobial activity [11](#).

α -Defensins	sequence
HNP-1	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
HNP-2	CYCRIPACIAGERRYGTCIYQGRLWAFCC
HNP-3	DCYCRIPACIAGERRYGTCIYQGRLWAFCC
HNP-4	VCSCRLVFCRRETLRVGNCLIGGVSTFYCCTRVD
HNP-5	ATCYCRTGRCATRESLSGVCEISGRLYRLCCR

α -Defensins	sequence
HNP-6	TCHCR-RSCYSTEYSYGTCTVMGINHRFCCL

β -defensins	sequence
hBD-1	GNFLTGLGHRSDHYN CVSSGGQCLYSACPIFTKIQT CYRGKAKCCK
hBD-2	GIGDPVTCCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP
hBD-3	GIINTLQKYYCVRVGGRCAVLSCLPKEEQIGKCSTRGRKCRRKK
hBD-4	EFELDRICGYGTARCRK-KCRSQEYRIGRC PN-TYACCLRKWDESLNRTKP

α -defensins

The α -defensins were described, which have been isolated from the granules of polymorphonuclear neutrophil leukocytes. Because of their distribution in the granules of the leucocytes, they were named human neutrophil peptides 1-4 (HNP1-4) [12](#). They are constitutively produced by myeloid precursor cells. However, recent reports suggest that their production can be induced by activated CD8 T cells as well [13](#), in contrast, HD-5 and HD-6 are enteric defensins stored in the granules of Paneth cells, processing of 'pro-HD-5' is mediated by one or more isoforms of Paneth cell trypsin [24](#). Although the main sites of human α -defensins production are leukocytes and Paneth cells, the human female reproductive tract expresses HD-5, When induced to degranulate, neutrophils and Paneth cells release these α defensins locally [14](#).

These six peptides are human α -defensins, whose typical structure consists of 29-35 amino acids. (Table1) demonstrates the difference in structure between α - and β -defensins.

α -defensins are synthesized as inactive prepro- α -defensins whose maturation requires the cleavage of a signal peptide to produce pro- α -defensins. Then, the NH₂-terminal neutralizing pro fragment is cleaved by cellular proteases [[???](#),[15](#),[16](#)]. Mature HNP-1, HNP-2 and HNP-3 appear to have similar bioactivities.

Mature HNP-1 3 are 3 kDa peptides comprising 6 characteristic, highly conserved cysteine residues and 3 intra-molecular disulfide bonds. HNP-2 is the smallest human defensin (29 amino-acids) and differs from HNP1 and HNP3 by the absence of only one, N-terminal amino-acid residue in HNP-1 is alanine and aspartate in HNP3 [17](#)

β -defensins

β -defensins are phylogenetically older and new family members continue to be identified, with approximately 40 potential coding regions on the human genome [18](#). A computational search strategy identified 28 new human β -defensin genes in five syntenic chromosomal regions. At least 26 of the predicted genes were found to be transcribed. [[???](#)]: 23060878. hBD-1 was the first β -defensin discovered [19](#). Although hBD-1 expression is primarily restricted to epithelium, it has been detected in peripheral blood [20](#) and was originally isolated from plasma filtrates of patients with end stage renal disease [[19](#),[21](#)]

Actually the platelets express and release hBD-1 protein in response to *S. aureus*-derived toxins. Platelets have also recently been shown to express and release hBD-3 protein. [21](#)

β -defensins were traditionally viewed as exclusively antimicrobial molecules, as their induction in response to diverse bacterial, viral, parasitic and fungal infections was widely reported [[22](#),[23](#)]. β -

defensins are preferentially attracted to the negatively charged outer membranes of bacteria, with reported efficacy against bacteria, fungi and enveloped viruses. [24](#).

##Mechanism of Action

The classical mechanism of action of cationic AMPs, such as defensins, is the disruption of the anionic bacterial membrane [25](#). This way, bacterial destruction occurs by the interaction between the electrostatic forces of positively charged amino acids and the negatively charged cell surface [\[8,26\]](#).

Bacterial membranes are rich in negatively charged phospholipids, such as phosphatidyl-glycerol (PG), cardiolipin (CL), and phosphatidylserine (PS); these are stabilized by bivalent cations such as Mg^{+2} and Ca^{+2} . Gram-negative bacteria have an additional lipopolysaccharide rich outer membrane, which stands as a barrier to the cytoplasmic membrane. On the other hand, human cells are rich in neutrally charged phospholipids, such as phosphatidylethanolamine (PE), phosphatidylcholine (PC), and sphingomyelin (SM). In humans, the interaction with AMPs is even less likely because of the presence of cholesterol, which affects the fluidity of phospholipids in the membrane and increases its stability [\[27\]](#); doi:10.1080/13102818.2019.1611385]

As for the membrane-permeabilizing mechanism, different models of interaction have been proposed (a) Barrel-stave pore model, in which the HDPs form dimers or multimers that cross the membrane forming barrel-like channels [\[??\]](#): 15582982 (b) Toroidal pore model, in which the peptide forms a monolayer by connecting the outer and the inner lipid layers in the pore @:pmid 25374459 (c) Carpet model, where HDPs form a carpet-like structure covering the outer surface of the membrane acting like detergents disrupting the bacterial membrane [27](#)

In a recent work, Mathew and Nagaraj proposed the ability of HD5 to strongly bind DNA as the basis of its mechanism of action, suggesting that this interaction may inhibit essential processes associated with DNA replication, transcription or translation of important genes [\[28,29\]](#)

the defensin has more implication, Defensin binding to viral attachment proteins could disrupt receptor interactions critical for viral entry into the cell. HNP1-3, HD5, and hBD-3 bind a recombinant viral glycoprotein (gB) of both HSV-1 and HSV-2, which correlates with the ability of these defensins to inhibit HSV-1 and HSV-2 entry and adhesion [30](#)

Viral infection can also induce defensin expression. For example, human rhinovirus induces hBD-2 in primary human epithelial cell cultures, although hBD-2 has no direct antiviral effect on the virus [31](#). Another example of how defensins can not only attack the pathogen, but can also induce the response of the immune system is β -Defensins exert regulatory activity in host innate and adaptive immune responses. For example, mouse β -defensin 2 activates Immature dendritic cells (DCs) via Toll-like receptor (TLR4), triggering a Th1 lymphocytes response, and human β -defensin 3 activates Antigen-presenting cells (APCs) via TLR1 and TLR2 in an NF- κ B-dependent manner [\[32,33\]](#)

Now a day we continue to discover new functions of the defensins, and therefore the mechanisms of action have not yet been fully elucidated, for example studies report that the use of human defenses to regulate host metabolism and mitigate dyslipidemia, and non alcoholic fatty liver disease NAFLD pmid:30860877. however, hard work is still being done to try to understand all the functions of the defensins, as well as their mechanisms of action.

Defensins and cancer

References

1. Defensins: antimicrobial peptides of innate immunity

Tomas Ganz

Nature Reviews Immunology (2003-09) <https://doi.org/cx6gzg>

DOI: [10.1038/nri1180](https://doi.org/10.1038/nri1180) · PMID: [12949495](https://pubmed.ncbi.nlm.nih.gov/12949495/)

2. Animal antimicrobial peptides: an overview.

D Andreu, L Rivas

Biopolymers (1998) <https://www.ncbi.nlm.nih.gov/pubmed/10333735>

DOI: [10.1002/\(sici\)1097-0282\(1998\)47:6<415::aid-bip2>3.0.co;2-d](https://doi.org/10.1002/(sici)1097-0282(1998)47:6<415::aid-bip2>3.0.co;2-d) · PMID: [10333735](https://pubmed.ncbi.nlm.nih.gov/10333735/)

3. Design of an α -helical antimicrobial peptide with improved cell-selective and potent anti-biofilm activity

Shi-Kun Zhang, Jin-wen Song, Feng Gong, Su-Bo Li, Hong-Yu Chang, Hui-Min Xie, Hong-Wei Gao, Ying-Xia Tan, Shou-Ping Ji

Scientific Reports (2016-06-08) <https://doi.org/ggt4kh>

DOI: [10.1038/srep27394](https://doi.org/10.1038/srep27394) · PMID: [27271216](https://pubmed.ncbi.nlm.nih.gov/27271216/) · PMCID: [PMC4897634](https://pubmed.ncbi.nlm.nih.gov/pmc/PMC4897634/)

4. PHAGOCYTIN: A BACTERICIDAL SUBSTANCE FROM POLYMORPHONUCLEAR LEUCOCYTES

James G. Hirsch

The Journal of Experimental Medicine (1956-05-01) <https://doi.org/dzvswf>

DOI: [10.1084/jem.103.5.589](https://doi.org/10.1084/jem.103.5.589) · PMID: [13319580](https://pubmed.ncbi.nlm.nih.gov/13319580/) · PMCID: [PMC2136631](https://pubmed.ncbi.nlm.nih.gov/pmc/PMC2136631/)

5. Defensins. Natural peptide antibiotics of human neutrophils.

T Ganz, ME Selsted, D Szklarek, SS Harwig, K Daher, DF Bainton, RI Lehrer

Journal of Clinical Investigation (1985-10-01) <https://doi.org/bb8wz4>

DOI: [10.1172/jci112120](https://doi.org/10.1172/jci112120) · PMID: [2997278](https://pubmed.ncbi.nlm.nih.gov/2997278/) · PMCID: [PMC424093](https://pubmed.ncbi.nlm.nih.gov/pmc/PMC424093/)

6. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain.

M Zanetti, R Gennaro, D Romeo

FEBS letters (1995-10-23) <https://www.ncbi.nlm.nih.gov/pubmed/7589491>

DOI: [10.1016/0014-5793\(95\)01050-o](https://doi.org/10.1016/0014-5793(95)01050-o) · PMID: [7589491](https://pubmed.ncbi.nlm.nih.gov/7589491/)

7. Mammalian defensins in the antimicrobial immune response

Michael E Selsted, Andre J Ouellette

Nature Immunology (2005-05-19) <https://doi.org/bcth9d>

DOI: [10.1038/ni1206](https://doi.org/10.1038/ni1206) · PMID: [15908936](https://pubmed.ncbi.nlm.nih.gov/15908936/)

8. Antimicrobial activity, mechanism of action, and methods for stabilisation of defensins as new therapeutic agents

Meri Amerikova, Ivanka Pencheva El-Tibi, Vania Maslarska, Stanislav Bozhanov, Konstantin Tachkov

Biotechnology & Biotechnological Equipment (2019-05-11) <https://doi.org/ggt6q5>

DOI: [10.1080/13102818.2019.1611385](https://doi.org/10.1080/13102818.2019.1611385)

9. Defensins and host defense.

T Ganz

Science (New York, N.Y.) (1999-10-15) <https://www.ncbi.nlm.nih.gov/pubmed/10577203>

DOI: [10.1126/science.286.5439.420](https://doi.org/10.1126/science.286.5439.420) · PMID: [10577203](https://pubmed.ncbi.nlm.nih.gov/10577203/)

10. **Defensins: endogenous antibiotic peptides of animal cells.**
RI Lehrer, T Ganz, ME Selsted
Cell (1991-01-25) <https://www.ncbi.nlm.nih.gov/pubmed/1988144>
DOI: [10.1016/0092-8674\(91\)90632-9](https://doi.org/10.1016/0092-8674(91)90632-9) · PMID: [1988144](https://pubmed.ncbi.nlm.nih.gov/1988144/)
11. **Antibacterial activity of human neutrophil defensin HNP-1 analogs without cysteines.**
Jobin Varkey, Ramakrishnan Nagaraj
Antimicrobial agents and chemotherapy (2005-11)
<https://www.ncbi.nlm.nih.gov/pubmed/16251296>
DOI: [10.1128/aac.49.11.4561-4566.2005](https://doi.org/10.1128/aac.49.11.4561-4566.2005) · PMID: [16251296](https://pubmed.ncbi.nlm.nih.gov/16251296/) · PMCID: [PMC1280114](https://pubmed.ncbi.nlm.nih.gov/PMC1280114/)
12. **Current status of defensins and their role in innate and adaptive immunity.**
Periathamby Antony Raj, Andrew R Dentino
FEMS microbiology letters (2002-01-02) <https://www.ncbi.nlm.nih.gov/pubmed/11786250>
DOI: [10.1111/j.1574-6968.2002.tb10979.x](https://doi.org/10.1111/j.1574-6968.2002.tb10979.x) · PMID: [11786250](https://pubmed.ncbi.nlm.nih.gov/11786250/)
13. **Defensin-rich granules of human neutrophils: characterization of secretory properties.**
Mikkel Faurschou, Ole E Sørensen, Anders H Johnsen, Jon Askaa, Niels Borregaard
Biochimica et biophysica acta (2002-08-19) <https://www.ncbi.nlm.nih.gov/pubmed/12183052>
DOI: [10.1016/s0167-4889\(02\)00243-4](https://doi.org/10.1016/s0167-4889(02)00243-4) · PMID: [12183052](https://pubmed.ncbi.nlm.nih.gov/12183052/)
14. **[Structure and function of enteric alpha defensins in norm and pathology].**
IG Nikitina, Iu A Bukurova, GS Krasnov, EN Grineva, VL Karpov, NA Lisitsyn, SF Beresten'
Molekuliarnaia biologii <https://www.ncbi.nlm.nih.gov/pubmed/22642099>
PMID: [22642099](https://pubmed.ncbi.nlm.nih.gov/22642099/)
15. **Posttranslational processing of defensins in immature human myeloid cells.**
EV Valore, T Ganz
Blood (1992-03-15) <https://www.ncbi.nlm.nih.gov/pubmed/1339298>
PMID: [1339298](https://pubmed.ncbi.nlm.nih.gov/1339298/)
16. **Intramolecular inhibition of human defensin HNP-1 by its propiece.**
EV Valore, E Martin, SS Harwig, T Ganz
The Journal of clinical investigation (1996-04-01) <https://www.ncbi.nlm.nih.gov/pubmed/8601627>
DOI: [10.1172/jci118588](https://doi.org/10.1172/jci118588) · PMID: [8601627](https://pubmed.ncbi.nlm.nih.gov/8601627/) · PMCID: [PMC507226](https://pubmed.ncbi.nlm.nih.gov/PMC507226/)
17. **Human defensins as cancer biomarkers and antitumour molecules.**
Nathalie Droin, Jean-Baptiste Hendra, Patrick Ducoroy, Eric Solary
Journal of proteomics (2009-01-11) <https://www.ncbi.nlm.nih.gov/pubmed/19186224>
DOI: [10.1016/j.jprot.2009.01.002](https://doi.org/10.1016/j.jprot.2009.01.002) · PMID: [19186224](https://pubmed.ncbi.nlm.nih.gov/19186224/)
18. **Human beta-defensins.**
M Pazgier, DM Hoover, D Yang, W Lu, J Lubkowski
Cellular and molecular life sciences : CMLS (2006-06)
<https://www.ncbi.nlm.nih.gov/pubmed/16710608>
DOI: [10.1007/s00018-005-5540-2](https://doi.org/10.1007/s00018-005-5540-2) · PMID: [16710608](https://pubmed.ncbi.nlm.nih.gov/16710608/)
19. **Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets.**
Hansjörg Schwertz, Neal D Tolley, Jason M Foulks, Melvin M Denis, Ben W Risenmay, Michael Buerke, Rachel E Tilley, Matthew T Rondina, Estelle M Harris, Larry W Kraiss, ... Andrew S Weyrich
The Journal of experimental medicine (2006-10-23)

<https://www.ncbi.nlm.nih.gov/pubmed/17060476>

DOI: [10.1084/jem.20061302](https://doi.org/10.1084/jem.20061302) · PMID: [17060476](https://pubmed.ncbi.nlm.nih.gov/17060476/) · PMCID: [PMC2118136](https://pubmed.ncbi.nlm.nih.gov/PMC2118136/)

20. Differential expression of alpha- and beta-defensins in human peripheral blood.

X-M Fang, Q Shu, Q-X Chen, M Book, H-G Sahl, A Hoeft, F Stuber

European journal of clinical investigation (2003-01)

<https://www.ncbi.nlm.nih.gov/pubmed/12492457>

DOI: [10.1046/j.1365-2362.2003.01076.x](https://doi.org/10.1046/j.1365-2362.2003.01076.x) · PMID: [12492457](https://pubmed.ncbi.nlm.nih.gov/12492457/)

21. Novel anti-bacterial activities of β -defensin 1 in human platelets: suppression of pathogen growth and signaling of neutrophil extracellular trap formation.

Bjoern F Kraemer, Robert A Campbell, Hansjörg Schwertz, Mark J Cody, Zechariah Franks, Neal D Tolley, Walter HA Kahr, Stephan Lindemann, Peter Seizer, Christian C Yost, ... Andrew S Weyrich

PLoS pathogens (2011-11-10) <https://www.ncbi.nlm.nih.gov/pubmed/22102811>

DOI: [10.1371/journal.ppat.1002355](https://doi.org/10.1371/journal.ppat.1002355) · PMID: [22102811](https://pubmed.ncbi.nlm.nih.gov/22102811/) · PMCID: [PMC3213094](https://pubmed.ncbi.nlm.nih.gov/PMC3213094/)

22. Expression of a beta-defensin mRNA, lingual antimicrobial peptide, in bovine mammary epithelial tissue is induced by mastitis.

Kara Swanson, Stas Gorodetsky, Laura Good, Stephen Davis, David Musgrave, Kerst Stelwagen, Vicki Farr, Adrian Molenaar

Infection and immunity (2004-12) <https://www.ncbi.nlm.nih.gov/pubmed/15557657>

DOI: [10.1128/iai.72.12.7311-7314.2004](https://doi.org/10.1128/iai.72.12.7311-7314.2004) · PMID: [15557657](https://pubmed.ncbi.nlm.nih.gov/15557657/) · PMCID: [PMC529112](https://pubmed.ncbi.nlm.nih.gov/PMC529112/)

23. Divergent antimicrobial peptide (AMP) and acute phase protein (APP) responses to Trypanosoma congolense infection in trypanotolerant and trypanosusceptible cattle.

Kieran G Meade, Grace M O'Gorman, Emmeline W Hill, Fernando Narciandi, Morris Agaba, Stephen J Kemp, Cliona O'Farrelly, David E MacHugh

Molecular immunology (2009-11-03) <https://www.ncbi.nlm.nih.gov/pubmed/19889461>

DOI: [10.1016/j.molimm.2009.09.042](https://doi.org/10.1016/j.molimm.2009.09.042) · PMID: [19889461](https://pubmed.ncbi.nlm.nih.gov/19889461/)

24. β -Defensins: Farming the Microbiome for Homeostasis and Health.

Kieran G Meade, Cliona O'Farrelly

Frontiers in immunology (2019-01-25) <https://www.ncbi.nlm.nih.gov/pubmed/30761155>

DOI: [10.3389/fimmu.2018.03072](https://doi.org/10.3389/fimmu.2018.03072) · PMID: [30761155](https://pubmed.ncbi.nlm.nih.gov/30761155/) · PMCID: [PMC6362941](https://pubmed.ncbi.nlm.nih.gov/PMC6362941/)

25. Human antimicrobial peptides and proteins.

Guangshun Wang

Pharmaceuticals (Basel, Switzerland) (2014-05-13)

<https://www.ncbi.nlm.nih.gov/pubmed/24828484>

DOI: [10.3390/ph7050545](https://doi.org/10.3390/ph7050545) · PMID: [24828484](https://pubmed.ncbi.nlm.nih.gov/24828484/) · PMCID: [PMC4035769](https://pubmed.ncbi.nlm.nih.gov/PMC4035769/)

26. Alpha defensins 1, 2, and 3: potential roles in dyslipidemia and vascular dysfunction in humans.

Abel López-Bermejo, Berta Chico-Julià, Antoni Castro, Mònica Recasens, Eduardo Esteve, Josefina Biarnés, Roser Casamitjana, Wifredo Ricart, José-Manuel Fernández-Real

Arteriosclerosis, thrombosis, and vascular biology (2007-02-15)

<https://www.ncbi.nlm.nih.gov/pubmed/17303777>

DOI: [10.1161/atvbaha.106.138594](https://doi.org/10.1161/atvbaha.106.138594) · PMID: [17303777](https://pubmed.ncbi.nlm.nih.gov/17303777/)

27. Human antimicrobial peptides and cancer.

Ge Jin, Aaron Weinberg

Seminars in cell & developmental biology (2018-05-31)

<https://www.ncbi.nlm.nih.gov/pubmed/29694838>
DOI: [10.1016/j.semcd.2018.04.006](https://doi.org/10.1016/j.semcd.2018.04.006) · PMID: [29694838](https://pubmed.ncbi.nlm.nih.gov/29694838/)

28. Perspectives for clinical use of engineered human host defense antimicrobial peptides.

María Eugenia Pachón-Ibáñez, Younes Smani, Jerónimo Pachón, Javier Sánchez-Céspedes
FEMS microbiology reviews (2017-05-01) <https://www.ncbi.nlm.nih.gov/pubmed/28521337>
DOI: [10.1093/femsre/fux012](https://doi.org/10.1093/femsre/fux012) · PMID: [28521337](https://pubmed.ncbi.nlm.nih.gov/28521337/) · PMCID: [PMC5435762](https://pubmed.ncbi.nlm.nih.gov/PMC5435762/)

29. Antimicrobial activity of human α -defensin 5 and its linear analogs: N-terminal fatty acylation results in enhanced antimicrobial activity of the linear analogs.

Basil Mathew, Ramakrishnan Nagaraj
Peptides (2015-07-20) <https://www.ncbi.nlm.nih.gov/pubmed/26206286>
DOI: [10.1016/j.peptides.2015.07.009](https://doi.org/10.1016/j.peptides.2015.07.009) · PMID: [26206286](https://pubmed.ncbi.nlm.nih.gov/26206286/)

30. Defensins in Viral Infection and Pathogenesis.

Mayumi K Holly, Karina Diaz, Jason G Smith
Annual review of virology (2017-07-17) <https://www.ncbi.nlm.nih.gov/pubmed/28715972>
DOI: [10.1146/annurev-virology-101416-041734](https://doi.org/10.1146/annurev-virology-101416-041734) · PMID: [28715972](https://pubmed.ncbi.nlm.nih.gov/28715972/)

31. Antiviral mechanisms of human defensins.

Sarah S Wilson, Mayim E Wiens, Jason G Smith
Journal of molecular biology (2013-10-02) <https://www.ncbi.nlm.nih.gov/pubmed/24095897>
DOI: [10.1016/j.jmb.2013.09.038](https://doi.org/10.1016/j.jmb.2013.09.038) · PMID: [24095897](https://pubmed.ncbi.nlm.nih.gov/24095897/) · PMCID: [PMC3842434](https://pubmed.ncbi.nlm.nih.gov/PMC3842434/)

32. Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2.

Nicholas Funderburg, Michael M Lederman, Zhimin Feng, Michael G Drage, Julie Jadowsky, Clifford V Harding, Aaron Weinberg, Scott F Sieg
Proceedings of the National Academy of Sciences of the United States of America (2007-11-15)
<https://www.ncbi.nlm.nih.gov/pubmed/18006661>
DOI: [10.1073/pnas.0702130104](https://doi.org/10.1073/pnas.0702130104) · PMID: [18006661](https://pubmed.ncbi.nlm.nih.gov/18006661/) · PMCID: [PMC2141828](https://pubmed.ncbi.nlm.nih.gov/PMC2141828/)

33. Human β -defensin 2 is involved in CCR2-mediated Nod2 signal transduction, leading to activation of the innate immune response in macrophages.

Ju Kim, Ye Lin Yang, Yong-Suk Jang
Immunobiology (2019-05-18) <https://www.ncbi.nlm.nih.gov/pubmed/31126693>
DOI: [10.1016/j.imbio.2019.05.004](https://doi.org/10.1016/j.imbio.2019.05.004) · PMID: [31126693](https://pubmed.ncbi.nlm.nih.gov/31126693/) · PMCID: [PMC7114636](https://pubmed.ncbi.nlm.nih.gov/PMC7114636/)